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Abstract
Background: This trial aims to evaluate effective delivery and cost effectiveness of an innovative
structured psycho-educational programme (CASCADE) for young people and their families living
with diabetes. The increase in numbers of people being diagnosed with diabetes is posing a
challenge for both the UK and the rest of the world. The peak age for diagnosis is between 10 and
14 years of age. There is clear evidence that improved diabetes control from diagnosis in childhood
can reduce the incidence and progression of long-term complications. However, despite the
development of improved insulin regimens and delivery methods, the overall metabolic control in
children and adolescents has improved little in the UK in the past decade. Therefore there is a need
for novel interventions and health delivery mechanisms aimed at young people and their families to
help improve control and reduce complications, illness burden and costs to the NHS.
Methods/Design: The CASCADE trial is a multi-centre randomised control trial with 26 clinics
randomised to control or intervention groups, with 572 children and young people involved in the
study. The intervention will be delivered in 4 group sessions, over a 4 month period. A
developmentally appropriate curriculum will be delivered to groups of 3 - 4 families, focusing on
achievement of increasing competency in self-management of diabetes. The control group will
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receive standard care from their clinical team, usually consisting of regular 3-monthly clinic visits
and telephone contact as required with the clinical nurse specialist and consultant. The primary
outcomes of the trial will be change in HbA1c between baseline and 12 months and 24 months post
recruitment. Secondary outcomes will include measures related to the economic evaluation,
psychosocial outcomes, outcomes related to management of diabetes outcomes, and adherence to
the intervention.
Discussion:  The trial will be run by independent research and service delivery teams and
supervised by a trial steering committee. A data monitoring and ethics committee has been put in
place to monitor the trial and recommend stopping/continuation according to a Peto-Haybittle
rule. The trial will be conducted according to the principles of MRC Good Clinical Practice (GCP)
Guidelines and CTRU Phase III Trial Standard Operating procedures.
Trial Registration: Current Controlled Trials ISRCTN52537669
Background
Diabetes burden
The increase in numbers of people being diagnosed with
diabetes is posing a challenge for both the UK and the rest
of the world. The World Health Organisation has named
this a "global pandemic", affecting the lives and welfare of
hundreds of millions of people with the condition as well
as carers and loved ones. This increase in burden has
occurred with type 1 as well as type 2 diabetes. The current
estimate of prevalence of Type I diabetes in the UK is 1 per
700-1000 children, yielding a total population aged
under 25 of approximately 15,000 -25,000. The peak age
for diagnosis is between 10 and 14 years of age.[1]
The long-term complications of diabetes include microv-
ascular and macrovascular disease, reduced life expect-
ancy (on average by 23 years in people with type 1
diabetes) and higher cardiovascular and all-cause mortal-
ity.[2] Complications are often first detected in adoles-
cence. There is clear evidence that improved diabetes
control from diagnosis in childhood can reduce the inci-
dence and progression of microvascular complications
including retinopathy, nephropathy and neuropathy.[3]
There is also evidence that later improved control reduces
complications, even after a history of poor control. [3-5]
Failure of new insulins and delivery systems to deliver 
hoped for benefits
Despite the research evidence of the benefits of intensive
insulin regimens and the potential benefits of the intro-
duction of new insulins and methods of insulin delivery
(e.g. insulin pumps), overall indices of metabolic control
in children and adolescents has improved little in the UK
in the past decade; currently only 14-20% of children and
young people with type 1 diabetes meet the recom-
mended HbA1c threshold of <7.5%.[6] The reasons for
this are unclear; In children and adolescents, failure to
improve diabetes control is thought to be related to issues
related to self- and family management of the implemen-
tation of intensive regimens in daily life and adjustment
to diabetes, particularly during the developmental
changes of adolescence.[7,8] Given the above, there is a
concerted search for novel interventions and health deliv-
ery mechanisms to help improve control and reduce com-
plications, illness burden and costs to the NHS. [8-10]
Educational programmes for modern intensive insulin 
regimens
The search for improved control has led to intensification
of diabetes regimens (by injections as well as pumps)
through carbohydrate counting and the use of insulin to
carbohydrate ratios for determining preprandial insulin
doses, together with the use of correction insulin doses
informed by insulin sensitivity ratios. This has led to the
development of adult education skills programmes to
train patients in the self-management of intensive regi-
mens without substantial professional support - e.g.
DAFNE (dose adjustment for normal eating) which have
been shown to be effective.[11] and cost-effective.[12] in
improving HbA1c by approximately 1% in adults.
Existing psycho-educational interventions
A recent randomised trial in the US (Svoren et al 2003)
showed that an intensive psycho-educational programme
allied to case-management resulted in 25% fewer total
hypoglycaemic events, 60% fewer severe hypoglycaemic
events, and 40% fewer hospitalizations and emergency
visits than did standard multi-disciplinary care or simple
case management approaches.[13] The importance of
integrating medical care and educational and psychoso-
cial interventions has been highlighted in the systematic
review published by Hampson et al (1999).[14] The
absence of high quality UK-based studies and the need for
a programme of primary research on interventions for
children and young people was also emphasised.[14]
The review found that the theoretical basis of the majority
of completed trials is family therapy. However, there is
often very little detail in the papers to be clear which
school of family therapy is informing the therapeuticBMC Pediatrics 2009, 9:57 http://www.biomedcentral.com/1471-2431/9/57
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delivery of material. A number of groups have used a fam-
ily/group based approach and obtained robust effect sizes
in either metabolic control and/or psychosocial out-
comes. [15-18] The evidence supports the clinical view
that developmentally appropriate negotiated responsibil-
ity has beneficial outcomes.
Effective components of successful programmes incorpo-
rate the integration of medical care and educational and
psychological interventions. An example of this is relating
self management of blood glucose (SMBG) to other
aspects of diabetes to demonstrate how information can
be used to guide other management behaviours. Multi-
component interventions are more successful than those
that focus on only one aspect in improving metabolic
control, particularly in adolescents. Additionally, there is
evidence that diabetes educators show significant
improvements in their skills in educating, supporting and
counselling patients when using alternative approaches to
traditional didactic methods.[19] Therefore interventions
must not only deliver knowledge but ensure it can be put
into practice.[20] Caring for children and young people
with diabetes is fundamentally different to providing serv-
ices for adults. It is a complex process that must be firmly
focused on the child or young person and their family
and/or other carers, supported by the skills and experi-
ences of a wide range of health care professionals. Consid-
eration must be given to the physical and emotional needs
of the developing and growing individual along with the
social constraints of family, friends, early years and
school, as well as adapting to different developmental
stages over time. A key component of effective chronic
care management involving young people and their fami-
lies or carers is establishing and maintaining the motiva-
tion that will enable them to manage the complex
juggling act required to achieve effective management of
their condition.[21]
One of the major concerns raised by parents and families
is access to quality information and advice in a timely
fashion and which is delivered in a consistent and evi-
dence based manner in a form that can be easily compre-
hended by the user. Conventional expert-centred
approaches relying on professional advice are usually
unavailable out of hours, which may be one reason for the
relatively low uptake of intensive management of type 1
diabetes in the UK. Intensive self-management pro-
grammes potentially offer a cost-effective way of meeting
family needs while also overcoming professional resource
limitations.
The UCL Hospitals diabetes team in partnership with fam-
ilies has developed an innovative psycho-educational pro-
gramme (CASCADE) that promotes engagement,
motivation and flexible self management, delivered in a
clinic setting with promising improvements in self man-
agement, psychological adjustment and long term meta-
bolic control. Previous work that has used psychological
approaches to promote engagement, motivation and
behaviour change, which resulted in a significant reduc-
tion in HbA1c,.[21] have been incorporated into the psy-
cho-educational programme. The intervention CASCADE
is based upon the findings of the HTA review.[14] and our
Phase 1 pilot work and includes a number of elements
shown to be important in predicting success in improving
long-term diabetic control as well as simply transferring
knowledge. Small improvements in diabetes control can
lead to significant improvements in long term health as
well as large savings in health care expenditure. In light of
this knowledge, the aim of the trial is to test the hypothe-
sis that CASCADE will provide a clinically effective inter-
vention that could be adopted at low cost throughout the
UK, without extensive employment of additional profes-
sionals. The Diabetes Control and Complications Trial
showed that a 1.5% reduction in HbA1c is associated with
a 40% or greater reduction in microvascular complica-
tions later in life.[3] There is evidence that reducing the
current UK paediatric mean HbA1c by 1% would reduce
by up to 50% the risk of developing retinopathy and renal
impairment over a 10 year period.[3] Evaluation of the
process of implementation, effectiveness and costs effec-
tiveness of CASCADE is being carried out by a multidisci-
plinary team of researchers from the Social Science
Research Unit at the Institute of Education, Medical Statis-
tics Unit and Health Services Research Unit at the London
School of Hygiene and Tropical Medicine, The School of
Pharmacy and Diabetes UK.
Objectives
1) To examine the implementation and assess the feasibil-
ity of the proposed structured intensive educational pro-
gramme (CASCADE) provided within a standard clinic
setting for a diverse range of young people.
2) To investigate the effects of the above intervention on
long term metabolic control of diabetes.
3) To evaluate the impact of the intervention on diabetes-
specific quality of life and psychosocial functioning.
4) To investigate the cost effectiveness of the intervention.
Methods/Design and Discussion
Design
The trial is a multi-centre cluster randomised control trial
involving 572 children and young people from 26 clinics
in central and southern England, with integral process and
economic evaluation. The process evaluation will moni-
tor the implementation (including extent of uptake) of
the intervention in experimental clinics and any alterna-
tive intervention (standard care) received by young peo-
ple and families attending control clinics; documentBMC Pediatrics 2009, 9:57 http://www.biomedcentral.com/1471-2431/9/57
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factors influencing the implementation of the interven-
tion; identify components of the intervention which con-
tribute to its effectiveness; assess the acceptability of the
interventions to young people, parents and clinic staff;
and examine perceived impact of the intervention on out-
comes Economic evaluation will include within-trial cost-
effectiveness analysis and a cost-utility analysis based on a
model combining data from the trial with data from the
literature. The perspective adopted will be that of the
NHS, that is, the economic evaluation will only consider
costs to the NHS and health benefits to patients
Endpoints of the study
Primary outcomes: Change in HbA1c between baseline
and 12 months and 24 months post recruitment.
Secondary outcomes will measure
(a) Diabetes outcomes directly related to patient management
(i) Diabetes regimen (insulin delivery/number of injec-
tions/insulin types) (ii) Hypoglycaemic episodes (fre-
quency, severity) (iii) Admissions to hospital and reason
(e.g. episodes of ketoacidosis, hypoglycaemia and (iv)
changes in levels of complexity and competency in self
management.[22]
(b) Psychosocial outcomes
(i) Health related quality of life (QOL): PedsQL with Dia-
betes module.[23] (ii) Diabetes Family Responsibility
Questionnaire.[24] (iii) Strengths and Difficulties Ques-
tionnaire (parent report).[25]
(c) Diabetes outcomes indirectly related to patient management
(i) Compliance with intervention/control (attendance at
intervention sessions) (ii) Service utilisation rate (Clinic
attendance/Number of contacts with diabetes nurse spe-
cialists and diabetes teams)
Economic evaluation will include within-trial cost-effec-
tiveness analysis and a cost-utility analysis based on a
model combining data from the trial with data from the
literature. The perspective adopted will be that of the
NHS, that is, the economic evaluation will only consider
costs to the NHS and health benefits to patients.
It should be noted that it will not be possible to directly
evaluate the effects of the intervention on diabetes com-
plications because of low incidence during adolescence.
Type of study
The trial is a multi-centre cluster randomised control trial.
572 children and families from 26 clinics in the regional
diabetes network covering central and southern England
will be recruited. This is an unblinded study as, once
recruited and randomised, clinics will be aware of
whether or not they are receiving the intervention or con-
trol treatment (see Figure 1).
Randomisation
As this is a cluster randomised trial, clinics will be ran-
domised to intervention or control groups. Randomisa-
tion will be minimised by factors likely to influence clinic
mean HbA1c; e.g. clinic age (paediatric or adolescent) and
the degree of clinic specialisation (district general hospital
clinic or teaching hospital/tertiary clinic).
Interventions - intervention group
The CASCADE intervention is delivered in 4 group ses-
sions (modules), delivered monthly over a 4 month
period. Content of each of the four modules is outlined in
Table 1. Each module will include the following educa-
tional and motivational structure:
i. Solution focused review and goal setting: Trainers invite
families to identify recent aspects of diabetic management
that have gone well to encourage them to see themselves
as experts in their diabetes and to help them identify
strengths, resources and abilities. Participants are encour-
aged to identify what they would find useful or helpful to
discuss and think about during the session. This ensures
that participants collaborate in the identification of learn-
ing objectives
ii. Enhancing motivation to change (Addressing ambiva-
lence): Desired behaviour change choices are discussed
using motivational enhancement techniques that address
ambivalence. Participants identify the pros and cons of
behaviour change acknowledging that any change in
behaviour will have both costs and benefits. Motivational
interviewing focuses on encouraging the individual to
identify the personal and systemic benefits of the desired
behaviour to them and their family.
Pre and post session knowledge will be evaluated with
specific goals set for what actions the young person plans
to initiate in between sessions.
Interventions - control group
Control families will continue to receive the usual stand-
ard care.[26] from their NHS clinical team, this usually
consists of regular 3-monthly medical clinic visits plus tel-
ephone contact as required with the clinical nurse special-
ist and consultant. The process evaluation will monitor
and describe standard care as well as the CASCADE inter-
vention.
Duration
The intervention will be delivered over a period of 4
months, and families will be followed-up 12 and 24
months post recruitment.BMC Pediatrics 2009, 9:57 http://www.biomedcentral.com/1471-2431/9/57
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Enrolment - inclusion criteria
Participating clinics will be recruited from central and
southern England. Participants aged between 8 and 16
years with a diagnosis of type 1 diabetes for one year or
more, and HbA1c = 8.5 (defined as mean 12 month
HbA1c = 8.5%) will be recruited from within these clinics.
An average of 80 - 100 young people per clinic will be eli-
gible to take part in the study with an expected recruit-
ment rate of 25% based on our pilot study.
Enrolment - exclusion criteria
Table 2 shows the enrolment exclusion criteria.
Enrolment - Sources/methods of enlisting participants in 
trial
Participating clinics will be randomly allocated to either
the intervention or control arm of the study. To reduce the
likelihood of bias resulting from differential recruitment
in the two trial arms, clinic staff will be asked to identify
eligible young people before the clinics have been ran-
domised, so as to be blind to the random allocation. Eli-
gible families will be sent a letter inviting them to take
part in a trial comparing different ways of helping young
people to manage their diabetes, making clear that all
approaches have potential advantages and disadvantages.
Researchers will then visit clinics to meet eligible families,
answer any questions that they might have and, if they
wish to participate, recruit them to the study. When
researchers cannot visit a clinic to meet an eligible family,
then recruitment will be carried out by local clinicians
using standardised procedures. Timing of clinic appoint-
ments (on average every 3 months) means that some eli-
gible families in all clinics will be recruited after
randomisation has been carried out. To reduce bias result-
ing from the lack of blinding at recruitment, families will
not be informed of the arm to which their clinic has been
randomised until they have decided whether or not to
participate in the study.
Enrolment - Losses to follow-up
We anticipate a drop out rate of approximately 10% and
have inflated our sample accordingly (see sample size cal-
culation below). We have been conservative in our esti-
mates of recruitment (25% of eligible), in line with our
previous experience. Note also that the motivational ele-
ments of this intervention are specifically designed to
enhance retention; Drop out during our previous motiva-
tional/solution-focused intervention.[21] was minimal
(approximately 5%) over a similar number of sessions.
For standard care, we estimate that loss to follow-up in
Flow Chart showing intervention and control treatment Figure 1
Flow Chart showing intervention and control treatment.
26 clinics recruited to the study 
Clinic staff identify eligible young people (total 572) 
Where possible families recruited to the study. Baseline information collected at recruitment. 
26 clinics randomised to either intervention or control arm 
Control 
Remaining young people recruited 
to the study from each clinic (total 
22).  Baseline data collected at 
recruitment 
.
Intervention 
Remaining young people recruited 
to the study from each clinic (total 
22). Baseline data collected at 
recruitment 
The young people receive standard 
care including regular 3 monthly 
visits. 
The intervention is delivered to the 
young people in 4 group sessions 
monthly over a 4 month period 
Follow up information collected at 
3,6, 12 and 24 months
Follow up information collected at 
3,6, 12 and 24 monthsBMC Pediatrics 2009, 9:57 http://www.biomedcentral.com/1471-2431/9/57
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our clinic is <10% per year. We will use regional and
national diabetes networks and Diabetes UK to maintain
contact with those lost to follow-up due to moving.
Consent
Consent to clinic randomisation will be obtained from
the responsible clinician. After clinic randomisation,
informed written consent or assent will be obtained for
participation in intervention or research procedures from
the young person and one parent after clinic randomisa-
tion, as per standard procedures for cluster randomised
trials.[27] The right of a child or parent to refuse participa-
tion without giving reasons will be respected. The child/
young person or their parent will remain free to withdraw
at any time from the study without giving reasons and
without prejudicing further treatment. If a participant
withdraws consent from further trial participation their
data will remain on file and will be included in the final
study analysis. If a participant withdraws consent for their
data to be used, the data will be destroyed immediately.
Sample size calculation
The standard deviation (SD) of HbA1c in the target popu-
lation is approximately 1.5%. We propose to recruit suffi-
cient young people to allow the trial to detect a difference
between groups of 0.5 standard deviations, i.e. 0.75%,
with 90% power at a significance level of 0.05 (2-tailed);
this is considered to represent a moderate size of effect.
This is a highly clinically meaningful effect, given that the
Diabetes Control and Complications Trial showed con-
Table 1: CASCADE module content
Module 1:
Living with Diabetes-challenges and choices
Module 3:
Adjusting insulin - pros and cons
Identification of strengths, resources and abilities
Why we need food - a healthy balance
How insulin works - happy and unhappy cells
What are carbohydrate foods and their effects
Insulin regimens and their action profiles
Enhancing motivation to change
(Post module quiz)
When to adjust insulin
When to get help
(urgent and non-urgent)
Recognising Hyperglycaemia
When & how to treat hyperglycaemia
Insulin stacking
Using an insulin sensitivity ratio
Adjusting insulin to food - CHO counting
Enhancing motivation to change
(Post module quiz)
Module 2:
BG testing - pros and cons
Module 4:
Food, activity and exercise
Reasons for testing BG levels
HbA1c and complications
Factors that influence the BG level (up and down)
Recognising Hypoglycaemia
How to treat Hypoglycaemia
Enhancing motivation to change
(Post module quiz)
Relationship between insulin action & exercise
Blueprint for success
Table 2: Exclusion criteria
1. Participants with significant mental health problems unrelated to diabetes that require specific mental health treatment.
2. Participants with significant other chronic illness in addition to diabetes that may be confound the results of the intervention.
3. Participants with significant learning disability or lack of command of English sufficient to render them unable to participant effectively in the 
planned intervention. Note that there is research evidence that the great majority of eligible young people from black or minority ethnic 
groups in this population have good command of English, although their parents may not. Given the wide range of ethnicities in the sample 
population, and given the importance of group dynamics to the intervention, it will not be possible to use interpreters to enable parents with 
poor English to participate. We will ensure that the validity of the study is maintained by including young people with good command of 
English. They will be eligible to attend sessions by themselves, or with another relative who is one of the primary diabetes carers (such as a 
sibling, aunt or uncle) who has good command of English and can participate instead of the parents.
4. While inclusive elsewhere, we will not recruit clinics which are unlikely to be able to recruit sufficient participants with a good command of 
English. We anticipate that this pertains to only one clinic within our sample area.
5. Young people who have participated in diabetes treatment trials in the 12 months prior to collection of baseline data will not be eligible for 
this trial.BMC Pediatrics 2009, 9:57 http://www.biomedcentral.com/1471-2431/9/57
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clusively that a reduction of approximately 1.5% in
HbA1c reduced the risk of microvascular complications in
adults by 40% (microalbuminuria) to 75% (retinopathy)
over 6.5 years,.[3] with similar benefits seen in adoles-
cents.[28] There is considerable other evidence that
smaller reductions in HbA1c, of the order of 0.5% are clin-
ically highly significant, e.g. the DCCT found a continu-
ous association of higher HbA1c and greater
microvascular risk.[3] The DAFNE trial in adults had an
effect size of approximately 1% reduction in HbA1c.[11]
Additionally, a reduction of 0.5 SD is half the effect size
identified in our pilot work (1.0 SD). Our power calcula-
tions are based upon an intracluster correlation coefficient
(ICC: the variability in outcome between clinics divided
by the sum of the within-cluster and between-cluster vari-
abilities) of 0.1. In the absence of reliable data on which
to calculate an ICC for the clinic population, this has been
chosen to be compatible with ICCs calculated from the
Northern Irish.[29] and Scottish audits,.[30] and data-
bases of ICCs such as http://www.abdn.ac.uk/hsru/epp/
cluster.shtml. With these assumptions, 13 clinics in each
arm with an average of 20 young people in each would be
required to detect a difference of half a standard deviation
(0.75) with over 90% statistical power at 5% significance.
Given the possible loss to follow up of approximately
10%, the target recruitment will be inflated to 22 young
people from each clinic. This is in line with the expected
25% anticipated recruitment rate as experienced in our
previous intervention study.
Methods
Data collection
A. HbA1c
This will be collected in two ways because of problems
with standardisation.
1. Venepuncture at baseline and 12 months and 24
months post recruitment: For the primary outcome,
HbA1c will be collected by venepuncture (by a skilled
local clinician) and transported to a single laboratory
(University College Hospital) for analysis. This will
ensure direct comparability of results from all clinics.
2. Routine clinical measurement of HbA1c (secondary
outcomes): It is standard practice to measure HbA1c 3
monthly and the researchers will assist the clinic staff in
ensuring that these data are obtained and recorded for all
participants at 3 and 6 months post recruitment. Values
from the different clinics will be standardised to DCCT
aligned values using an accepted approach.
B. Questionnaires
A range of diabetic, economic, psychosocial and quality of
life data will be collected at baseline and 12 and 24
months post recruitment using standardised question-
naires. Participants, parents and clinic staff as appropriate
will complete questionnaires in clinic. Researchers will
provide support where necessary.
C. Economic data
In addition to HbA1c and questionnaire data on service
use, data on costs of the intervention will be carefully
recorded by researchers and clinic staff.
D. Process evaluation data
Qualitative and quantitative data will be collected
through i) observation of training of clinic staff and deliv-
ery of intervention sessions with young people and par-
ents ii) focus groups with young people and parents iii)
interviews with trainers, clinic staff delivering sessions to
young people and other stakeholders iv) structured ques-
tionnaires with young people and clinic staff. Trained
researchers who have extensive experience of working
with young people and other staff and who have no
involvement in the design or delivery of the intervention
will carry out all data collection.
Proposed type and frequency of data analysis
Quantitative data analysis
HbA1c data and other quantitative data from structured
questionnaires will be analysed using STATA (StataCorp,
Statistical Software: Release 10.0. 2005, Stata Corpora-
tion: College Station, TX.). All primary analyses will be
carried out according to the principle of intention-to-treat
and taking into account the clustering. Every effort will be
made to obtain outcome measures on participants, even if
some drop out during the course of the group sessions.
The data will be analysed by multiple regression model-
ling, fitting baseline measures of outcomes as covariates.
The small groups in which experimental and control inter-
ventions are delivered will be fitted as a random effect. A
small number of secondary analyses based on explicit
hypotheses, such as subgroup and explanatory analyses
considering compliance with the interventions, will be
specified in advance. Interim analyses will be reported in
confidence to the independent Data Monitoring Commit-
tee.
Qualitative data analysis
Data from observations, interviews and focus groups as
well as open-ended questionnaire responses will be ana-
lysed using a system of coding and memoing developed
by Lofland and Lofland (1995),.[31] facilitated by the use
of NVivo software. First, the key topics and issues that
emerged from the data will be identified through familiar-
isation with transcripts or documents. Pertinent excerpts
that illustrate emerging themes will be coded and memos
written to summarise and synthesise these emerging
themes. In an iterative process, researchers will refine their
analysis, ensuring that the themes built up are cross-
checked with other data. To maximise the validity of our
findings, two researchers will separately analyse a sampleBMC Pediatrics 2009, 9:57 http://www.biomedcentral.com/1471-2431/9/57
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of the qualitative data and then meet to compare their
analyses and agree a framework for full analysis of all
data.
Analysis for Economic evaluation
The economic evaluation will assess the potential cost-
effectiveness of the structured intervention. Cost will be
compared to standard education during clinic appoint-
ments. A successful intervention will result in better gly-
caemic control, which could improve life expectancy and
improve health-related quality of life (partly as a result of
a reduction in complications). The impact on resource use
will have two main elements: the cost of delivering the
intervention (including the costs of training of relevant
staff); and future changes in resource use as a consequence
of a successful intervention.
The within-trial analysis will be in the form of a cost-effec-
tiveness analysis estimating the incremental cost per unit
change in glycosylated haemoglobin levels achieved 24
months post recruitment. However, such a measure of
cost-effectiveness is of limited value in informing decision
making because it is not clear how much the NHS should
be willing-to-pay in order to achieve improvements in
metabolic control, it only permits comparison with a very
narrow range of other interventions, and it ignores longer
term health benefits and health care cost savings as a
result of a successful intervention. Therefore, the cost-
effectiveness of the intervention will also be estimated
over a longer time horizon and in terms of cost per qual-
ity-adjusted life-year gained. This will be achieved by com-
bining information from the trial (the impact on HbA1c
and the incremental cost of the structured intensive inter-
vention) with estimates of other parameters from the lit-
erature. This will involve constructing a model of future
health care resource use and health outcome (in terms of
survival and health-related quality of life) based on the
changes in HbA1c observed over follow-up. Successful
modelling beyond the two year follow-up of the trial will
depend particularly on the specification of the relation-
ship between changes in HbA1c and the risk of complica-
tions, and on the evidence in the literature on the health
utilities associated with different diabetes-related health
states. Deterministic and probabilistic sensitivity analyses
will be undertaken to reflect the considerable uncertainty
regarding these and other aspects of the model.
Confidentiality
All information collected during the course of the trial will
be kept strictly confidential. Information will be held
securely on paper and electronically in the SSRU (process
evaluation) and LSHTM (outcome evaluation). The study
will comply with all aspects of the 1998 Data Protection
Act and operationally this will include
1. Consent from children and parents to record per-
sonal details including name, date of birth, address
and telephone number, GP name and address and
NHS number
2. Appropriate storage, restricted access and disposal
arrangements for personal and clinical details
3. Consent from children for the data collected for the
trial to be used to develop new research. The child's
name, address and telephone number will be collected
when they are randomised into the trial but all other
data collection forms that are transferred to or from
the CTRU will be coded with a trial number and will
include two identifiers, usually their initials and date
of birth.
4. Consent from patients for access to their medical
records by responsible individuals from the research
staff, where it is relevant to trial participation
Ethical Approval
The trial will be performed in accordance with the recom-
mendations guiding physicians in biomedical research
involving human participants adopted by the 18th World
Medical Assembly, Helsinki, Finland, 1964, amended at
the 59th World Medical Association General Assembly,
Seoul, October 2008. The study has been approved by the
UCL/UCLH Research Ethics Committee (REC; reference
number 07/HO714/112).
Organisation and Governance
Project Management Group (PMG)
A project management group will be established and will
be responsible for the day to day management of the trial.
The group will comprise the principal investigators and
project staff from each of the institutions involved in the
trial. The group will meet monthly in person and by tele-
phone.
The study combines expertise from five multidisciplinary
institutions with strong cross professional links:
• Development and implementation of the structured
psycho-educational intervention will be carried out by
the UCLH diabetes team, led by the principal investi-
gator Dr Deborah Christie.
￿ Coordination of the trial including recruitment of
trials participants, ensuring procedures for obtaining
informed consent from participants, data collection
and analysis of process data will be carried out by a
team of independent researchers from the Social Sci-
ence Research Unit at the Institute of Education andBMC Pediatrics 2009, 9:57 http://www.biomedcentral.com/1471-2431/9/57
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UCL School of Pharmacy. Trial coordination will be
led by Dr Vicki Strange
￿ A team from the Medical Statistics Unit (led by Prof
Diana Elbourne and Dr Elizabeth Allen) at the Lon-
don School of Hygiene and Tropical Medicine will
provide expertise regarding trial design and undertake
the randomisation and all statistical analysis.
￿ Professor John Cairns, a member of the London
School of Hygiene and Tropical Medicine Health Serv-
ices Research Unit, will supervise all economic aspects
of this research
Trial steering committee
The Steering Committee will approve the main study pro-
tocol, monitor and supervise the trial towards its interim
and overall objectives, review relevant information from
other sources, consider the recommendations of the
DMC, and resolve problems brought by the trial co-ordi-
nating centres. The committee will comprise an independ-
ent chairperson and 2 independent members, as well as
the members of the project management group. This rep-
resents all the different disciplines involved in the trial.
Data Monitoring Committee
An independent Data Monitoring Committee (DMC) will
review, in strict confidence, data from the trial approxi-
mately half way through the recruitment period. The
Chair of the DMC may also request additional meetings/
analyses. In the light of these data, and other evidence
from relevant studies, the DMC will inform the Steering
Committee, if in their view i) there is proof beyond rea-
sonable doubt that the data indicate that any part of the
protocol under investigation is either clearly indicated or
contra-indicated, either for all patients or for a particular
subgroup, or ii) it is evident that no clear outcome will be
obtained with the current trial design.
Unless modification or cessation of the protocol is recom-
mended by the DMC, the Steering Committee, collabora-
tors and administrative staff (except those who supply the
confidential information) will remain ignorant of the
results of the interim analysis.
Membership of the Data Monitoring Committee
Professor Christopher Kelnar, University of Edinburgh; Dr
Robert Coe, Durham University; Dr Chris Patterson,
Queen's University Belfast; Dr Darren Ashcroft, School of
Pharmacy and Pharmaceutical Sciences.
Publication policy
The results of the study will conform to the CONSORT
statement for the reporting of cluster RCTs.[32] and be
disseminated widely to the clinical community as well as
to participants. To safeguard the scientific integrity of the
trial, data from this study will not be presented in public
or submitted for publication without requesting com-
ments and receiving agreement from the Trial Steering
Committee. As the success of the trial depends on the col-
laboration of many people, the primary results of the trial
will be published by the group as a whole although the
paper will be written by a smaller writing committee, and
a table of contributors will delineate individual investiga-
tors' personal contributions to the study.
Advisory group of research and service users
Ensuring that service users and potential users of research
are involved in the design and governance of the proposed
trial is a key objective of this study. To facilitate the
involvement of users, the research team will convene a
steering group of research and service users. This will
include representatives from key policy makers and clini-
cians. This will meet three times during the study and will
provide an opportunity for the research team to consult
about the research design and methods for data collec-
tion, choice of outcomes and methods for data analyses.
This advisory group will have an important role in inter-
preting initial findings and developing dissemination
strategies.
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